Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The minimum requirement for candidate human immunodeficiency virus (HIV) vaccines to enter clinical evaluation in humans should be their demonstrable immunogenicity in non-human primates: induction of antibodies neutralizing primary HIV isolates or elicitation of broad T cell-mediated immune responses. Here, we showed in rhesus macaques that the very same vaccines that had entered clinical trials in Oxford and Nairobi, plasmid pTHr.HIVA DNA and recombinant modified vaccinia virus Ankara MVA.HIVA in a prime-boost protocol (Hanke & McMichael, Nature Medicine 6, 951-955, 2000), induced cellular immune responses specific for multiple HIV-derived epitopes. This was demonstrated by using the intracellular cytokine staining and ELISPOT assays detecting interferon-gamma and pools of peptides employed in the clinical studies. These results have both boosted our expectations for the performance of these vaccines in humans and increased our confidence about the choice of these assays as the primary readouts in the on-going human trials.

Original publication

DOI

10.1099/0022-1317-83-1-75

Type

Journal article

Journal

J Gen Virol

Publication Date

01/2002

Volume

83

Pages

75 - 80

Keywords

AIDS Vaccines, Animals, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cells, Cultured, DNA, Viral, Gene Products, gag, Genetic Vectors, HIV Antigens, HIV Core Protein p24, HIV-1, Humans, Interferon-gamma, Kenya, Macaca mulatta, Vaccines, DNA, Vaccinia virus, Viral Proteins, gag Gene Products, Human Immunodeficiency Virus